fda warning letters glp-1 october 2025 news issued 25 to telehealth companies for false and misleading claims about compounded products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA warns telehealth companies over

While efficacy endpoints for weight loss in those trials were modest, the compound exhibited a favorable safety profile, supporting its later GRAS designation for food use

[DOI] [PMC free article] [PubMed] [Google Scholar] 53.Dugbartey G.J., Alornyo K.K., Diaba D.E., Adams I

n=23 animal, including 76 human offspring, and an unknown number of animal offspring as these numbers could not be retrieved from the FDA and EMA product information)

Lowering stomach emptying

Dicks, 2024

Increased Pericyte Coverage of the Tumor Vasculature Heterogeneous pericyte coverage has been described in several types of tumors, at different stages of tumor progression, and even within a single tumor stage (Hida et al., 2013)